Oncoloxía médica
Servizo
Juan Antonio
Virizuela Echaburu
Publicacións nas que colabora con Juan Antonio Virizuela Echaburu (14)
2023
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2020
2019
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2017
-
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356
-
Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (Clin Transl Oncol, 10.1007/s12094-016-1535-8)
Clinical and Translational Oncology
-
Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists
Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518
2016
-
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242
-
SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan
Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 499-507
2013
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
2012
-
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2
Anti-Cancer Drugs, Vol. 23, Núm. 2, pp. 239-246
2010
-
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)
The Lancet Oncology, Vol. 11, Núm. 4, pp. 350-357
2009
-
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
Breast Cancer Research and Treatment, Vol. 116, Núm. 2, pp. 351-358
2005
-
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial
Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438
2004
-
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial
Seminars in Oncology, Vol. 31, Núm. 2 SUPPL. 5, pp. 20-24